Cipla gains on getting DCGI’s nod to launch Ciplenza in India to treat mild to moderate COVID-19

27 Jul 2020 Evaluate

Cipla is currently trading at Rs. 669.10, up by 3.60 points or 0.54% from its previous closing of Rs. 665.50 on the BSE.

The scrip opened at Rs. 678.80 and has touched a high and low of Rs. 678.80 and Rs. 667.70 respectively.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 696.20 on 17-Jul-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 691.40 and Rs. 658.00 respectively. The current market cap of the company is Rs. 53659.80 crore.

The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 39.92% and 23.40% respectively.

Cipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options in the country through restricted emergency use.

As part of its efforts to enable speedy access to cater to the demand, the company will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet. To ensure fair and equitable distribution of the drug, supplies will be undertaken predominantly through hospital channels and via open channels, prioritised for regions with a high burden of COVID-19 cases.

The drug has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology (IICT). As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective synthetic process for Favipiravir. The entire process and Active Pharmaceutical Ingredient (API) of the drug has been transferred to Cipla to manufacture and market the drug at scale.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1517.20 5.10 (0.34%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×